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Abstract 
Bovine necrohemorrhagic enteritis is caused by Clostridium perfringens and leads to sudden death. Alpha toxin, 
together with perfringolysin O, has been identified as the principal toxin involved in the pathogenesis. We assessed 
the potential of alpha toxin as a vaccine antigen. Using an intestinal loop model in calves, we investigated the protec‑
tion afforded by antisera raised against native alpha toxin or its non‑toxic C‑terminal fragment against C. perfringens‑
induced intestinal necrosis. Immunization of calves with either of the vaccine preparations induced a strong anti‑
body response. The resulting antisera were able to neutralize the alpha toxin activity and the C. perfringens‑induced 
endothelial cytotoxicity in vitro. The antisera raised against the native toxin had a stronger neutralizing activity than 
those against the C‑terminal fragment. However, antibodies against alpha toxin alone were not sufficient to com‑
pletely neutralize the C. perfringens‑induced necrosis in the intestinal loop model. The development of a multivalent 
vaccine combining the C‑terminal fragment of alpha toxin with other C. perfringens virulence factors might be neces‑
sary for complete protection against bovine necrohemorrhagic enteritis.
© 2016 Goossens et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Clostridium perfringens is a Gram-positive, spore-form-
ing, anaerobic bacterium. It is a normal component of 
the intestinal microbiota of animals, including humans. 
It secretes several toxins and enzymes that cause differ-
ent forms of tissue damage [1–3]. Consequently, it can 
cause a variety of diseases in various vertebrates [2]. The 
differences in virulence properties between C. perfringens 
isolates are largely due to differences in toxin production. 
Alpha toxin and perfringolysin O have been identified 
as the principal toxins involved in gas gangrene caused 
by C. perfringens as well as in bovine necrohemorrhagic 
enteritis [4]. Gas gangrene is a frequently lethal histotoxic 
infection of humans and animals characterized by rapid 
tissue destruction and impaired immune response [5, 6]. 
Bovine necrohemorrhagic enteritis (bovine enterotox-
aemia) is an enteric disease of veal calves and beef type 
suckling calves and is characterized by hemorrhagic to 
necrotizing enteritis. Calves often die without premoni-
tory signs [4, 7–9].
We recently showed that vaccination of calves with a 
mixture of native toxins from C. perfringens induces anti-
bodies that protect against C. perfringens challenge in an 
intestinal loop model of bovine necrohemorrhagic enter-
itis (Goossens et  al., provisionally accepted). Although 
both alpha toxin and perfringolysin O are involved in 
the pathogenesis of gas gangrene, immunization against 
alpha toxin alone provides good protection against 
experimental gas gangrene [6, 10, 11]. Moreover, Evans 
showed that antiserum raised against alpha toxin was 
highly effective in protecting guinea pigs against experi-
mental gas gangrene, whereas antiserum to perfringoly-
sin O was not protective against C. perfringens type A 
infection, and it did not enhance the protective action of 
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alpha toxin antiserum [12]. Studies on gas gangrene can-
not be directly extrapolated to bovine necrohemorrhagic 
enteritis, but these findings indicate that alpha toxin vac-
cines could provide protection against diseases in which 
alpha toxin is critically important.
Here, we tested vaccine preparations based on alpha 
toxin, the major toxin produced by C. perfringens type 
A. Since native toxins are not safe, we used the enzymati-
cally inactive C–terminal domain of alpha toxin (Cpa247–
370). This component is non-toxic and has been shown 
to provide protection against C. perfringens type A gas 
gangrene in a mouse model, and it is known to elicit 
protective immunity against a broad range of clostridial 
phospholipase C toxins [10, 13, 14]. In addition, mice 
vaccinated with Cpa247–370 were protected against chal-
lenge with alpha toxin derived from a calf necrohemor-
rhagic enteritis isolate [15].
The aim of this study was to evaluate whether the non-
toxic C-terminal fragment of alpha toxin could be a can-
didate for effective vaccination of calves against bovine 
necrohemorrhagic enteritis.
Materials and methods
All experimental protocols were approved by the eth-
ics committee of the Faculty of Veterinary Medicine, 
Ghent University (EC2011/024, EC2012/056, EC2013/38, 
EC2013/39 and EC2013/187). All animal experiments 
were carried out in accordance with the approved 
guidelines.
Bacterial strains
The C. perfringens strains were wild-type strain JIR325, 
the plc mutant JIR4107 (∆plc), and the C. perfringens 
JIR4107 derivatives carrying either the plc+ plasmid 
(complemented strain JIR4121) or the empty shuttle vec-
tor (complementation control JIR4120) (Table 1) [16, 17]. 
The strains were cultured anaerobically at 37 °C in Brain 
Heart Infusion broth (BHI, Oxoid, Basingstoke, UK) con-
taining 0.375% glucose. To culture JIR4120 [∆plc; (shuttle 
vector)] and JIR4121 (complemented strain), the medium 
was supplemented with chloramphenicol (30  µg/mL). 
The logarithmic phase cultures used in intestinal loop 
experiments did not contain antibiotics. To determine 
the alpha toxin concentration in the culture superna-
tant, cell-free supernatants were obtained by centrifuga-
tion followed by filtration of the supernatants through 
a 0.22-µm filter. The alpha toxin concentration in the 
bacterial supernatants was measured using the Bio-X 
α-toxin ELISA kit (Bio-X Diagnostics, Jemelle, Belgium) 
and twofold serial dilutions of the alpha toxin standard 
(220 × 10−3‒0.8 × 10−3 U/mL of phospholipase C type 
I; Sigma-Aldrich, St Louis, MO, USA) as previously 
described [18].
The role of C. perfringens alpha toxin in the induction 
of necrotic lesions in an intestinal loop model
To confirm the role of alpha toxin in the induction of 
necrotic lesions in an intestinal loop model, seven intesti-
nal loop experiments were conducted using the wild-type 
C. perfringens strain JIR325 and the alpha toxin-deficient 
strain C. perfringens JIR4107. In two of the experiments, 
the C. perfringens JIR4107 derivatives carrying the empty 
shuttle vector (JIR4120) or the plc+ plasmid (JIR4121) 
were also included. The number of loops injected with 
each strain is shown in Table  2. In each calf, an equal 
number of control loops were injected with sterile bac-
terial growth medium supplemented with milk replacer. 
The experiments were performed according to a pub-
lished protocol using seven healthy male Holstein–Frie-
sian veal calves aged 3‒5 months [19]. Briefly, the calves 
were anesthetized and the small intestine was exterior-
ized. The loops were ligated and injected with logarith-
mic phase cultures combined with 25% commercial milk 
replacer (Vitaspray, Nuscience Drongen, Belgium) in 
sterile 0.9% NaCl solution, as described [19]. The animals 
were kept under anesthesia for 5  hours after inocula-
tion, after which they were euthanized and samples were 
taken. Intestinal loop tissue samples were submerged in 
4% (w/v) phosphate buffered formaldehyde. After fixation 
for 24  h, the samples were processed routinely, embed-
ded in paraffin wax, sectioned, and stained with hema-
toxylin and eosin. Sections were evaluated in a blinded 
Table 1 Clostridium perfringens strains used in the study
a plc: alpha toxin gene.
b JIR325: a rifampicin and nalidixic acid-resistant derivative of strain 13, a C. perfringens strain originally isolated from soil.
Straina Strain number Phenotype Origin Toxin genes Alpha toxin (*10−3 U/mL) 
mean ± SEM
Ref.
Wild‑type JIR325 Wild‑type Strain 13b plc 31.392 ± 0.079 [16]
∆plc JIR4107 Alpha toxin‑deficient JIR325 Δplc <0.8 [17]
∆plc (shuttle vector) JIR4120 Alpha toxin‑deficient with shuttle 
vector
JIR4107(pJIR418) <0.8 [17]
complemented JIR4121 Alpha toxin‑ complemented JIR4107(pJIR443) plc 28.32 ± 0.38 [17]
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manner by a board certified pathologist for the presence 
of tissue necrosis (0 = absence of necrosis, 1 = necrotic 
lesions present).
Preparation of recombinant alpha toxin
Alpha toxin was expressed in Escherichia coli using the 
pBAD TOPO® TA Expression Kit (Invitrogen, Pais-
ley, UK). A fragment encoding the C. perfringens alpha 
toxin (plc gene; GenBank accession number BAB79742) 
was amplified from the DNA of C. perfringens JIR325 by 
PCR using a DNA polymerase with proofreading activ-
ity (Accuzyme, Bioline, Randolph, MA, USA). The for-
ward primer (5′- G TGA GAG GAG GAT ATA AAA 
ATG AAA AGA AAG ATT TGT AAG GCG -3′) con-
tained an in-frame stop codon and translation re-ini-
tiation sequence to remove the N-terminal leader and 
allow native protein expression. The reverse primer (5′- 
G TTT CTT TTT TAT ATT ATA AGT TGA ATT TCC 
TGA AAT CCA CTC -3′) excluded the native plc gene 
stop codon and included the C-terminal V5 epitope and 
polyhistidine region for affinity purification. The result-
ing PCR product was incubated with Taq polymerase for 
10 min at 72 °C (5 U; Promega, Madison, WI, USA) to add 
3′ A-overhangs, cloned into the pBAD-TOPO expression 
vector, and transformed into One Shot TOP10® E. coli. 
The correct orientation of the alpha toxin insert was veri-
fied by Sanger sequencing.
Escherichia coli carrying the pBAD-alpha toxin vec-
tor was grown at 37  °C to an OD600 of 0.4‒0.5 in Ter-
rific Broth supplemented with 100  µg/mL ampicillin. 
Expression of recombinant C. perfringens alpha toxin 
was induced for 4 h by adding L-arabinose to a final con-
centration of 0.002% (w/v). Bacteria were harvested by 
centrifugation and lysed enzymatically using BugBuster 
(Invitrogen). Alpha toxin was purified on a Ni-Sepha-
rose column (His Gravitrap, GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden) according to the manufacturer’s 
instructions. Subsequently, the protein was dialyzed 
against PBS, purity was analyzed using SDS-PAGE, and 
protein concentration was measured using BCA protein 
assay (Thermo Fisher Scientific, Waltham, MA, USA).
Vaccine preparation and immunization
The recombinant carboxy-terminal domain of alpha 
toxin fused to glutathione-S-transferase (GST) was 
kindly provided by Prof. Titball, University of Exeter, UK. 
This Cpa247–370 was produced in E. coli and was therefore 
devoid of any other C. perfringens proteins [20]. Recom-
binant native alpha toxin (rCpa) and Cpa247–370 were 
formulated with the adjuvant QuilA (Brenntag Biosec-
tor, Frederikssund, Denmark) in PBS. Each animal was 
injected with 1.5 mL of the filter-sterilized (0.2 µm) for-
mulation containing 350  µg antigen and 750  µg QuilA. 
Control animals received 750 µg QuilA in 1.5 mL PBS.
Six male Holstein–Friesian calves aged 2 months were 
used. They were housed on straw and received water and 
hay at libitum, and concentrates adjusted to the body 
weight.
For each antigen (rCpa, Cpa247–370 or QuilA control), 
two calves were immunized subcutaneously in the neck. 
The calves received a primer vaccination at the age of 
2  months, and booster immunizations 14 and 28  days 
later.
Enzyme‑linked immunosorbent assay
The immune response following vaccination was meas-
ured using serum samples obtained 2 weeks after the final 
booster immunization. Alpha toxin-specific antibody lev-
els were determined by the end-point dilution method 
using a blocking ELISA (C. perfringens alpha toxin sero-
logical ELISA kit, Bio-X Diagnostics). Sera were used at 
a dilution 1:50 and assays were performed in duplicate. 
The specific antibody level was expressed as percent 
inhibition according to the following formula:  % inhibi-
tion = [(OD negative − OD sample)/OD negative] × 100.
Neutralization of the hemolytic activity of wild‑type C. 
perfringens JIR325 alpha toxin on blood agar plates in vitro
Incubation of cell-free supernatants of the wild-type 
strain JIR325 (concentrated tenfold using Vivaspin, Sar-
torius Stedim Biotech GmbH, Göttingen, Germany) on 
sheep blood agar at 37  °C overnight results in an inner, 
complete zone of hemolysis caused by perfringolysin O 
and a less complete outer zone caused by alpha toxin. 
The sera’s ability to neutralize alpha toxin activity was 
assessed by incubating the JIR325 supernatant with an 
equal volume of the pooled sera from the two animals 
Table 2 The number of loops inoculated with each strain 
in the intestinal loop experiments to evaluate the role of C. 
perfringens alpha toxin in the induction of necrotic lesions
Seven intestinal loop experiments were conducted. The number of intestinal 
loops that were injected per animal are shown.
a JIR325: wild-type C. perfringens; JIR4107: alpha toxin-deficient; JIR4120: alpha 
toxin-deficient strain carrying the empty shuttle vector; JIR4121: alpha toxin-
complemented strain; BHI: sterile bacterial growth medium.
Calf Replicate loops/straina
JIR325 JIR4107 JIR4120 JIR4121 BHI
1 3 3 / / 3
2 3 3 / / 3
3 3 3 / / 3
4 5 5 / / 5
5 5 5 / / 5
6 5 5 5 5 5
7 5 5 5 5 5
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that were vaccinated with either a given vaccine or the 
adjuvant QuilA for 30 min at 37 °C. Ten-microliter drops 
of these mixtures were spotted on sheep blood agar and 
hemolysis was assessed after overnight incubation. The 
test was performed in triplicate using supernatants of 
C. perfringens JIR325 from three independent biological 
replicates.
Neutralization of alpha toxin activity on egg yolk 
lipoproteins
Alpha toxin activity was determined in duplicate in a 
96-well microtiter plate by evaluating its effect on egg 
yolk lipoproteins as previously described [21]. The neu-
tralizing ability of sera was assessed by pre-incubating a 
twofold dilution series of the sera (two wells per dilution) 
with a constant amount of alpha toxin (10 µg/mL in PBS) 
for 30 min at 37 °C before adding 10% egg yolk emulsion. 
To prepare the yolk emulsion, fresh egg yolk was centri-
fuged (10 000 × g for 20 min at 4 °C) and diluted 1:10 in 
PBS. After incubation of the 96-well plates at 37  °C for 
1  h, absorbance was measured at 650  nm. Alpha toxin 
activity was indicated by the development of turbid-
ity, which increases absorbance. The inhibitory capac-
ity of the antiserum was expressed as the serum dilution 
that inhibited 50% of the alpha toxin activity. This was 
determined by applying a Hill function to the concentra-
tion–response data (GraphPad Prism 5, GraphPad Soft-
ware, San Diego, CA, USA). The test was performed in 
duplicate.
Neutralization of C. perfringens cytotoxicity to bovine 
endothelial cells
Primary bovine umbilical vein endothelial cells (BUVEC) 
were isolated from umbilical cord veins by an adapted 
procedure [4] based on the method of Jaffe et al. [22]. The 
toxicity of C. perfringens supernatant to cultured bovine 
endothelial cells has been reported [4]. The ability of the 
antisera to neutralize the C. perfringens cytotoxicity to 
BUVECs was determined using a Neutral Red Uptake 
assay (NRU) [23]. Briefly, BUVEC cells were seeded in 
96-well tissue culture plates at a density of 105 cells per 
well and cultured for 24 h to obtain cells in the exponen-
tial growth phase. The neutralizing ability of the sera was 
assessed by pre-incubating a twofold dilution series of 
the sera (100–0.4%) prepared in serum-free cell culture 
medium with an equal volume of undiluted C. perfrin-
gens supernatant. After 30  min at 37  °C, the cells were 
treated for 2  h with 100  µL of the supernatant‒serum 
mixture, followed by a standard NRU assay. The inhibi-
tory capacity of the antiserum was expressed as the last 
dilution associated with 100% cell viability. As a positive 
control, cells were treated with C. perfringens superna-
tant pre-incubated with serum-free medium. Untreated 
cells incubated with serum-free medium served as a neg-
ative control. The test was performed in duplicate.
Neutralization of necrotic lesion development in the 
intestinal loop model
To study the protection against C. perfringens-induced 
necrosis provided by the antisera obtained from calves 
vaccinated with the respective vaccines, three intesti-
nal loop experiments were performed using three male 
Holstein–Friesian calves aged 3  months. In each of the 
three intestinal loop experiments, the sera for each vac-
cine were pooled. Intestinal loops were inoculated with a 
wild-type strain (JIR325) combined with 25% commercial 
milk replacer suspended in sterile NaCl solution. Before 
inoculation, serum from calves immunized with the dif-
ferent vaccine preparations was added to the NaCl solu-
tion containing milk replacer to a final concentration of 
6% serum (v/v). In each calf, five intestinal loops were 
injected with anti-Quil A, five with anti-native alpha 
toxin, and five with anti-C-terminal fragment of alpha 
toxin. Moreover, five control loops per calf were injected 
with C. perfringens without addition of serum (positive 
control) and five with sterile bacterial growth medium 
(negative control). This totaled 25 injected loops per calf. 
Samples were collected and scored as described for the 
intestinal loop experiments using the alpha toxin-defi-
cient strain.
Statistical analysis
Differences in the development of necrotic loops 
between the wild-type and the mutant C. perfringens 
strains were analyzed using multivariable logistic regres-
sion. The protective effect of the different antisera against 
development of intestinal necrosis in the loop model 
was determined by multivariable logistic regression. To 
account for clustering of loops within a calf, a fixed factor 
was included describing in which calves the experiments 
were performed. Significance was set at p  <  0.05 and 
analyses were performed in SPSS v. 22.0 (IBM Corpora-
tion, New York, USA). Results were reported as means 
and standard errors of the means (SEM).
Results
Clostridium perfringens alpha toxin‑deficient strain has a 
decreased ability to cause necrotic lesions in an intestinal 
loop model
A wild-type strain and an alpha toxin-deficient strain 
(∆plc) were tested in an intestinal loop model. The wild-
type strain caused necrotic lesions in 62.1% (18/29) of the 
injected loops, whereas the alpha toxin-deficient strain 
induced necrosis in significantly fewer loops (3.4%; 1/29) 
(p < 0.001). To confirm the role of alpha toxin in lesion 
development by complementing the deficiency, the ∆plc 
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derivatives carrying the empty shuttle vector (JIR4120) 
or the plc+ plasmid (JIR4121) were used. Necrotic lesions 
were observed in only one of the ten (10%) loops injected 
with the alpha toxin-deficient strain carrying the empty 
shuttle vector. This is significantly fewer than in the loops 
inoculated with the wild-type strain (62.1%; p =  0.008). 
The plc-complemented strain induced necrotic lesions 
in 50% (5/10) of the loops, which is comparable to the 
effect of the wild-type strain. No lesions were detected 
in the control loops treated with sterile bacterial culture 
medium (Figures 1 and 2). 
Antibody responses against alpha toxin in calves
After vaccination with native alpha toxin, the non-toxic 
C-terminal domain of alpha toxin or the adjuvant QuilA, 
serum antibodies produced against native alpha toxin 
were analyzed by ELISA. In all calves vaccinated with the 
native toxin or with the C-terminal domain, a strong anti-
body response against alpha toxin was detected 6 weeks 
after the first immunization. The calves vaccinated with 
the native toxin had antibody titers of 69.7 ± 7.8. Calves 
vaccinated with the non-toxic C-terminal domain of 
alpha toxin had antibody titers of 91.1  ±  1.6. No anti-
alpha toxin response was measured in the calves vacci-
nated with the adjuvant QuilA.
Neutralization of alpha toxin activity in vitro
Sheep blood agar was used to examine in  vitro neu-
tralization of alpha toxin activity of a wild-type C. per-
fringens strain by sera from calves immunized with the 
native alpha toxin (rCpa) or the non-toxic C-terminal 
fragment of the alpha toxin (Cpa247–370). Plates treated 
with C. perfringens supernatant exhibited both the 
inner (perfringolysin O) and outer (alpha toxin) zones 
of hemolysis. Incubation of the supernatant with sera 
against either rCpa or Cpa247–370 did not result in an 
outer zone of hemolysis, indicating neutralization of 
alpha toxin activity. These sera had no effect on perfrin-
golysin O activity. Incubation with sera from the control 
calves (QuilA) had no effect on C. perfringens toxin activ-
ities (Figure 3).
To determine whether the antisera against the vaccines 
can neutralize the lecithinase activity of alpha toxin, 
serial dilutions of the antisera were incubated with alpha 
toxin and its activity was measured on egg yolk lipopro-
teins. The sera of calves immunized with either the native 
alpha toxin (rCpa) or the C-terminal fragment of alpha 
toxin (Cpa247–370) decreased the activity of alpha toxin, 
with an inhibitory capacity of respectively 1189.0 ± 390.4 
for anti-rCpa or 323.8 ± 133.3 for the sera raised against 
Cpa247–370. No effect on alpha toxin activity was observed 
after incubation with sera from calves immunized only 
with QuilA.
Neutralization of the cytotoxicity of C. perfringens 
to bovine endothelial cells by anti‑alpha toxin antisera
To determine whether the antisera against the vaccines 
can inhibit the cytotoxicity of C. perfringens, serial dilu-
tions of the antisera were incubated with C. perfrin-
gens supernatant. Exposure of the endothelial cells to 
untreated supernatant resulted in 100% cell death. Anti-
sera raised against either the native alpha toxin (rCpa) or 
the C-terminal fragment of alpha toxin (Cpa247–370) pro-
tected the endothelial cells from C. perfringens cytotox-
icity. Sera from the control calves did not neutralize the 
C. perfringens-induced cytotoxicity. Pre-incubating the 
Figure 1 C. perfringens-induced necrosis in experimentally infected intestinal loops in calves. (A) Representative histological section from 
an intestinal loop injected with sterile bacterial growth medium. There are no lesions in this negative control loop. (B) Representative histological 
section from an intestinal loop injected with the wild‑type C. perfringens strain, showing hemorrhages and necrosis of the villi. HE, bars 200 µm.
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C. perfringens supernatant with a 288-fold dilution (±96) 
of the native alpha toxin antiserum resulted in 100% 
neutralization of cytotoxicity, whereas a 32-fold dilution 
(±0.0) of the antiserum against the C-terminal fragment 
(Cpa247–370) was needed to neutralize the cytotoxicity.
Protective effect of anti‑alpha toxin antisera against C. 
perfringens‑induced necrosis in an intestinal loop model
Neutralization of the lesion-inducing potential of C. per-
fringens by sera raised against the respective vaccines was 
evaluated in the intestinal loop model. Thirteen of the 
fifteen (86.7%) positive control loops inoculated with C. 
perfringens developed necrosis. Injection of loops with 
C. perfringens combined with sera from control calves 
(immunized with the adjuvant QuilA) also resulted in 
a high percentage of necrotic loops (93.3% of the loops, 
14/15). Injection of loops with C. perfringens combined 
with antisera raised against native alpha toxin (rCpa) 
resulted in significantly fewer necrotic loops as com-
pared to the loops containing C. perfringens and the 
QuilA antisera (p  =  0.028) and borderline significantly 
fewer necrotic loops as compared to the untreated loops 
(p = 0.054) (53.3% of the loops or 8/15). Antisera raised 
against the non-toxic C-terminal fragment of alpha toxin 
(Cpa247–370) did not significantly neutralize the lesion-
inducing ability of C. perfringens (10/15 or 66.7% necrotic 
loops) (Figure 4).
Discussion
Alpha toxin is involved in the induction of necrotic 
lesions in a calf intestinal loop model and is thus an 
important toxin in the pathogenesis of enterotoxaemia. 
We previously showed that alpha toxin production by C. 
perfringens is required for intestinal virulence by using 
a double-mutant C. perfringens strain devoid of alpha 
toxin and perfringolysin O, which was complemented 
for perfringolysin O to generate an alpha toxin-defi-
cient phenotype [4]. In the present study, we supported 
our earlier conclusions by using an alpha toxin-mutant 
strain. Mutant strains are frequently used to evaluate the 
Figure 2 Percentage of necrotic loops after C. perfringens 
inoculation. Intestinal loops inoculated with sterile cell culture 
medium (n = 29), the wild‑type strain (n = 29), the alpha toxin‑defi‑
cient strain (Δplc) (n = 29), the alpha toxin deficient strain carrying 
the empty shuttle vector [Δplc (shuttle vector)] (n = 10) and the alpha 
toxin‑complemented strain (n = 10) were histologically examined for 
the presence of tissue necrosis. The graph represents the percentage 
of loops in which necrotic lesions were present after 5 h of incubation 
with logarithmic stage cultures. ** 0.001 ≤ P < 0.01 and ***P < 0.001 
indicate a significant difference relative to the loops inoculated with 
the wild‑type strain.
Figure 3 In vitro neutralization of the hemolytic activity of the alpha toxin of C. perfringens. Supernatants of C. perfringens (+contr.) were 
either left untreated or were pre‑incubated with serum from calves immunized with native alpha toxin (rCpa), the non‑toxic C‑terminal fragment 
of alpha toxin (Cpa247–370) or the adjuvant QuilA. They were then spotted on sheep blood agar and incubated overnight at 37 °C. Neutralization of 
alpha toxin activity results in absence of an outer zone of hemolysis. +, no neutralization of toxin activity; −, complete neutralization of toxin activ‑
ity. Representative pictures of one out of three independent experiments.
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virulence effect of C. perfringens genes. A mutant strain 
was used to show that NetB is crucial for the induction 
of avian necrotic enteritis [24]. This approach also identi-
fied beta toxin as an essential virulence factor of C. per-
fringens type C in infected rabbits [25]. Moreover, Awad 
et al. used mutant strains to demonstrate that both alpha 
toxin and perfringolysin O are involved in the pathogen-
esis of gas gangrene [17, 26]. In our study, we confirmed 
that alpha toxin is required for intestinal virulence in a 
calf intestinal loop model. This conclusion was based on 
genetic evidence showing that an alpha toxin-deficient 
strain has a decreased ability to cause necrotic lesions 
in this model. The alpha toxin-complemented strain 
regained the ability to cause the disease, unambiguously 
fulfilling Falkow’s molecular Koch’s postulates [27].
In the present study, alpha toxin appeared to be a 
promising vaccine component against bovine necrohe-
morrhagic enteritis. Antisera raised against native alpha 
toxin reduced the lesion-inducing potential of C. perfrin-
gens in the intestinal loop model. However, alpha toxin 
is a potent dermonecrotic toxin that is not safe for use 
in calves. Alpha toxin can be rendered safe by formalde-
hyde treatment, but a well-known problem of this treat-
ment is that it might reduce immunogenicity [5, 28–30]. 
Therefore, a recombinant C. perfringens alpha toxoid 
may be preferable to a formaldehyde toxoid. The immu-
nogenicity of the C-terminal fragment of alpha toxin in 
calves was recently reported for the first time [31]. How-
ever, the ability of the antiserum derived after vaccina-
tion of calves with Cpa247–370 to neutralize the toxicity of 
C. perfringens to bovine cells or bovine intestine has not 
been evaluated [31]. Here, we report that the non-toxic 
C-terminal domain of alpha toxin (Cpa247–370) may be 
an effective alternative to the use of native alpha toxin. 
Indeed, calves immunized with the native alpha toxin or 
with the C-terminal domain of alpha toxin developed a 
strong immune response against alpha toxin. Neverthe-
less, compared to antisera against the native alpha toxin, 
sera from calves immunized with the C-terminal frag-
ment of alpha toxin showed weaker inhibition of the 
alpha toxin activity and weaker neutralization of the C. 
perfringens-induced endothelial cytotoxicity in  vitro. 
Additionally, the lesion-inducing potential of C. per-
fringens in the intestinal loop model was significantly 
reduced only by co-administration of antisera from ani-
mals vaccinated with the native alpha toxin.
The diminished protection afforded by antisera against 
the C-terminal domain may be attributed to the GST tag 
fused to the C-terminal domain of alpha toxin for protein 
purification purposes. Distortion of the conformation 
of the alpha toxin fragment by the GST tag has already 
been suggested in a previous study reporting that the 
untagged fragment was more protective against experi-
mental gas gangrene than the C-terminal fragment fused 
to the GST tag [13]. In contrast to the C-terminal frag-
ment of alpha toxin, the recombinant native alpha toxin 
used in this study was fused to a HIS tag for purification. 
This HIS tag is substantially smaller than the GST tag and 
is less likely to influence the conformation of the alpha 
toxin. This construct might generate more antibodies 
against the conformational epitopes that are important 
for protection. Alternatively, it may be that, in addition to 
antibodies directed to the C-terminal fragment of alpha 
toxin, also antibodies against the N-terminal fragment 
are needed to provide protection. However, a previous 
study showed that immunization with the N-terminal 
domain of alpha toxin was not protective against experi-
mental gas gangrene [13]. It is believed that membrane 
binding induces a conformational change in the N-termi-
nal domain from the closed to open configuration, which 
could reduce the affinity of antibodies raised against the 
N-terminal domain and complicates the development of 
protective antibodies against this N-terminal region [32, 
33]. Moreover, the combination of both toxin domains as 
vaccine antigen is not straightforward because combina-
tion of both non-toxic fragments restores the biological 
activity of alpha toxin [34].
Figure 4 Neutralization of the lesion-inducing potential of 
C. perfringens. The graph represents the percentage of intestinal 
loops in which necrotic lesions were present after 5 h of incubation 
with five treatments: sterile culture medium, C. perfringens alone 
(untreated) or C. perfringens in combination with 6% antiserum to 
either native alpha toxin (rCpa antiserum), antiserum to the non‑toxic 
C‑terminal fragment of alpha toxin (Cpa247–370 antiserum), or antise‑
rum from calves immunized with adjuvant only (QuilA antiserum). 
The graph represents the data from three intestinal loop experiments 
(total of 15 loops per condition).
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Total protection was not obtained even after vacci-
nation with native alpha toxin. It is possible that not all 
alpha toxin was neutralized by the antisera, leaving resid-
ual active alpha toxin to exert cytotoxicity. We also do not 
know whether in the field serum antibodies leaking into 
the intestinal lumen after intestinal damage will be suf-
ficient to inhibit alpha toxin and the induction of necrotic 
lesions. This should be tested in a subsequent study by 
performing intestinal loop experiments in immunized 
animals without adding antiserum to the ligated intes-
tinal loops. It is possible that total protection against 
development of intestinal lesions also requires other neu-
tralizing antibodies, for example, against perfringolysin 
O and/or other C. perfringens proteins. Therefore, other 
C. perfringens proteins in addition to alpha toxin and per-
fringolysin O might have to be incorporated in a vaccine 
to obtain complete protection. This is also the case for 
avian necrotic enteritis, where NetB is essential to cause 
disease, but vaccination with NetB provides only partial 
protection against C. perfringens challenge [35–37].
Endothelial damage is probably a key event in the 
pathogenesis of bovine necrohemorrhagic enteritis [4, 
19]. Initial epithelial damage could enable alpha toxin to 
penetrate the epithelial barrier and to act on endothe-
lial cells. In addition to other infectious agents, such as 
coccidia, enteropathogenic bacteria, coronaviruses and 
rotaviruses, several C. perfringens factors can contribute 
to initial epithelial damage, such as collagenase (kappa 
toxin), hyaluronidase (mu toxin) and mucinase [38–41]. 
More research is needed to investigate the role of these 
factors in the pathogenesis of necrohemorrhagic enteri-
tis and the protective effect of neutralizing antibodies 
against these proteins.
In this study, we used the calf intestinal loop model 
to evaluate the vaccine potential of C. perfringens alpha 
toxin. Ideally, vaccinated animals should be challenged 
with crude toxins or bacterial cultures to obtain con-
clusive evidence that vaccination against C. perfringens 
alpha toxin protects against bovine necrohemorrhagic 
enteritis. However, no challenge model for testing vac-
cine candidates in calves is yet available [19, 31, 42]. The 
intestinal loop model remains currently the best available 
model.
In conclusion, this study shows that the non-toxic 
C-terminal domain of alpha toxin is a promising antigen 
for vaccine development. Although antibodies against C. 
perfringens alpha toxin neutralize alpha toxin activity and 
C. perfringens-induced endothelial cytotoxicity in  vitro, 
antibodies against alpha toxin alone are inadequate 
for complete neutralization of C. perfringens-induced 
necrosis in the intestinal loop model of bovine necrohe-
morrhagic enteritis. The development of a multivalent 
vaccine combining the C-terminal fragment of alpha 
toxin with other still unidentified C. perfringens viru-
lence factors might be necessary for complete protection 
against bovine necrohemorrhagic enteritis.
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